Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoHKSE:09887 +8.04%10 Market Cap is HK$14,837.3 Mil as of Aug. 25, 2026. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, Nanjing Leads Biolabs Co ranks better than 86.29% on this metric.
Nanjing Leads Biolabs Co's quarterly market cap
stayed the same
from Dec. 2024 (HK$0.0 Mil) to Jun. 2025 (HK$0.0 Mil) but then
increased
from Jun. 2025 (HK$0.0 Mil) to Dec. 2025 (HK$9,849.1 Mil).
Nanjing Leads Biolabs Co's annual market cap
stayed the same
from Dec. 2023 (HK$0.0 Mil) to Dec. 2024 (HK$0.0 Mil) but then
increased
from Dec. 2024 (HK$0.0 Mil) to Dec. 2025 (HK$9,849.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nanjing Leads Biolabs Co's Enterprise Value for Today is HK$12,255.1 Mil.
Nanjing Leads Biolabs Co (HKSE:09887) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nanjing Leads Biolabs Co Market Cap Related Terms
Nanjing Leads Biolabs Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Market Cap Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
9,849.13
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Market Cap
0.00
0.00
0.00
0.00
9,849.13
HKSE:09887 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nanjing Leads Biolabs Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (HKSE:09887) has a Market Cap of HK$14,837.3 Mil as of Aug. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanjing Leads Biolabs Co and its competitors. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #195 out of 1422 companies in the Biotechnology industry, placing it in the top 13.7%.
Is Nanjing Leads Biolabs Co's Market Cap too high?
Nanjing Leads Biolabs Co's current Market Cap is HK$14,837.3 Mil. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #195 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #195 out of 1422 companies for Market Cap. This places Nanjing Leads Biolabs Co in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.73, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median Market Cap is 121.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current Market Cap is HK$14,837.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Market Cap of HK$14,837.3 Mil. The current Market Cap is HK$14,837.3 Mil. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Market Cap is HK$14,837.3 Mil as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score
Get the complete analysis for HKSE:09887
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09887 has been successfully added to your 
